Close Menu

NEW YORK — Opti Medical Systems said on Friday that it has received CE marking for its PCR-based SARS-CoV-2 test kit.

The Opti SARS-CoV-2 RT-PCR kit is designed to detect viral RNA extracted from nasopharyngeal swabs, oropharyngeal swabs, bronchoalveolar lavage, and sputum samples. It provides results within three and a half hours, the company said.

The kit received Emergency Use Authorization (EUA) from the US Food and Drug Administration in May.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.


This webinar will describe a rapid metagenomics assay under development for human pathogens, including the SARS-CoV-2 coronavirus.

Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.


This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.